Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Quantitative Assessment of the Effect of Chronic Kidney Disease on the Nonrenal Clearance of 10 Drugs After Intravenous Administration.

Hinderling PH, Yu Y.

Clin Pharmacol Drug Dev. 2019 Feb;8(2):138-151. doi: 10.1002/cpdd.635. Epub 2018 Dec 27. Erratum in: Clin Pharmacol Drug Dev. 2019 Jul;8(5):695.

PMID:
30589517
2.

The Pharmacokinetics of Potassium in Humans Is Unusual.

Hinderling PH.

J Clin Pharmacol. 2016 Oct;56(10):1212-20. doi: 10.1002/jcph.713. Epub 2016 Mar 8. Review.

PMID:
26854277
3.

Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract.

Hinderling PH, Karara AH, Tao B, Pawula M, Wilding I, Lu M.

J Clin Pharmacol. 2007 Jan;47(1):19-25.

PMID:
17192498
4.

The pH dependency of the binding of drugs to plasma proteins in man.

Hinderling PH, Hartmann D.

Ther Drug Monit. 2005 Feb;27(1):71-85.

PMID:
15665750
5.

Importance of using controls in in vivo experiments.

Graf LL, Young DA, Kressin DC, Marlar RA, Jacob GB, Hinderling PH.

Radiology. 2004 Oct;233(1):297-8; author reply 298-9. No abstract available.

PMID:
15454626
6.

Evaluation of a novel method to estimate absolute bioavailability of drugs from oral data.

Hinderling PH.

Biopharm Drug Dispos. 2003 Jan;24(1):1-16.

PMID:
12516074
7.

The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.

Lichtman SM, Etcubanas E, Budman DR, Eisenberg P, Zervos G, D'Amico P, O'Mara V, Musgrave K, Cascella P, Melikian A, Hinderling PH, Ferrer JM, Williams GJ.

Cancer Invest. 2002;20(7-8):904-13.

PMID:
12449721
8.

Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia.

Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH.

J Pharmacokinet Pharmacodyn. 2001 Dec;28(6):555-75.

PMID:
11999292
9.

Biased estimates of nonrenal clearance.

Hinderling PH.

J Pharm Sci. 2001 Jul;90(7):960-6.

PMID:
11458343
10.

Inhibition of thrombin by iopromide in vitro.

Graf LL, Young DA, Kressin DC, Marlar RA, Jacob GB, Hinderling PH.

Ther Drug Monit. 2001 Apr;23(2):93-9.

PMID:
11294523
11.

Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia.

Saul JP, Ross B, Schaffer MS, Beerman L, Melikian AP, Shi J, Williams J, Barbey JT, Jin J, Hinderling PH; Pediatric Sotalol Investigators.

Clin Pharmacol Ther. 2001 Mar;69(3):145-57.

12.

Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia.

Saul JP, Schaffer MS, Karpawich PP, Erickson CC, Epstein MR, Melikian AP, Shi J, Karara AH, Cai B, Hinderling PH.

J Clin Pharmacol. 2001 Jan;41(1):35-43.

PMID:
11144992
13.

Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects.

Barbey JT, Sale ME, Woosley RL, Shi J, Melikian AP, Hinderling PH.

Clin Pharmacol Ther. 1999 Jul;66(1):91-9.

PMID:
10430114
14.
15.

Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics.

Hinderling PH.

Pharmacol Rev. 1997 Sep;49(3):279-95. Review. No abstract available. Erratum in: Pharmacol Rev 2000 Sep;52(3):473.

PMID:
9311024
16.

Comparative serum estradiol profiles from a new once-a-week transdermal estradiol patch and a twice-a-week transdermal estradiol patch.

Harrison LI, Riedel DJ, Chang SF, Jacobson JP, Sellers JA, Kanniainen CM, Crowley JK, Hinderling PH.

Ther Drug Monit. 1997 Feb;19(1):37-42.

PMID:
9029744
17.

Pharmacokinetics of sematilide in renal failure.

Shi J, Ripley E, Gehr TW, Sica DA, Dandekar KA, Hinderling PH.

J Clin Pharmacol. 1996 Feb;36(2):131-43.

PMID:
8852389
18.

Kinetics and dynamics of sematilide.

Shi J, Lasser T, Koziol T, Hinderling PH.

Ther Drug Monit. 1995 Oct;17(5):437-44.

PMID:
8585104
19.

Single-dose interaction study of diprafenone HCl and propranolol HCl in healthy volunteers.

Hinderling PH, Tendolkar A, Dee CM, Barr WH, Seiberling M, Duerr H.

J Clin Pharmacol. 1995 Jul;35(7):721-9.

PMID:
7560253
20.

Absolute bioavailability estimated from oral data.

Hinderling PH, Shi J.

J Pharm Sci. 1995 Mar;84(3):385-6. No abstract available.

PMID:
7616383
21.

Comparative kinetics of sematilide in four species.

Hinderling PH, Dilea C, Koziol T, Millington G.

Drug Metab Dispos. 1993 Jul-Aug;21(4):662-9.

PMID:
8104126
22.

Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans.

Hinderling PH, Hartmann D.

Ther Drug Monit. 1991 Sep;13(5):381-401.

PMID:
1957331
23.

[Developments in drugs and populations at risk].

Hinderling PH.

Schweiz Rundsch Med Prax. 1989 Mar 21;78(12):321-5. German.

PMID:
2711078
25.
27.
28.

Comparative pharmacokinetics and cardiovascular effects of tiapamil in healthy volunteers and patients with hepatic cirrhosis.

Hinderling PH, Eckert M, Gasic S, Eichler HG, Pötzi R, Heizmann P.

Eur J Clin Pharmacol. 1986;31(4):397-404.

PMID:
3816918
29.

Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. II: Pharmacodynamics.

Hinderling PH, Gundert-Remy U, Schmidlin O, Heinzel G.

J Pharm Sci. 1985 Jul;74(7):711-7.

PMID:
4032241
30.

Integrated pharmacokinetics and pharmacodynamics of atropine in healthy humans. I: Pharmacokinetics.

Hinderling PH, Gundert-Remy U, Schmidlin O.

J Pharm Sci. 1985 Jul;74(7):703-10.

PMID:
4032240
31.
32.

Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man.

Hinderling PH, Schmidlin O, Seydel JK.

J Pharmacokinet Biopharm. 1984 Jun;12(3):263-87.

PMID:
6150103
33.

Pharmacokinetics of the antirheumatic proquazone in healthy humans.

Hinderling PH, Roos A.

J Pharm Sci. 1984 Mar;73(3):332-40.

PMID:
6716240
34.

The pharmacokinetics of furazlocillin in healthy humans.

Hinderling PH, Gundert-Remy U, Förster D, Gau W.

J Pharmacokinet Biopharm. 1983 Feb;11(1):5-30.

PMID:
6875810
35.

Atropine: a sensitive gas chromatography-mass spectrometry assay and prepharmacokinetic studies.

Eckert M, Hinderling PH.

Agents Actions. 1981 Nov;11(5):520-31.

PMID:
7337075
36.

Specific assay for radiolabelled digoxin and its known apolar metabolites in biological fluids. I.

Eichhorst O, Hinderling PH.

J Chromatogr. 1981 Jun 12;224(1):67-93.

PMID:
7263822
37.

Protein binding and erythrocyte partitioning of the antirheumatic proquazone.

Roos A, Hinderling PH.

J Pharm Sci. 1981 Mar;70(3):252-7.

PMID:
7264886
38.

Significance of the pharmacokinetics of antimicrobial drugs.

Hinderling PH.

Scand J Infect Dis Suppl. 1978;(14):25-35.

PMID:
279979
39.

Comparative studies of the protein binding of digoxin and its metabolites.

Hinderling PH.

Agents Actions. 1977 Sep;7(3):379-82.

PMID:
596321
41.

Pharmacokinetics of beta-methyldigoxin in healthy humans III: Pharmacodynamic correlations.

Hinderling PH, Garrett ER.

J Pharm Sci. 1977 Mar;66(3):326-9.

PMID:
851492
42.

Pharmacokinetics of beta-methyldigoxin in healthy humans II: Oral studies and bioavailability.

Hinderling PH, Garrett ER, Wester RC.

J Pharm Sci. 1977 Mar;66(3):314-25.

PMID:
845795
43.

Pharmacokinetics of beta-methyldigoxin in healthy humans I: intravenous studies.

Hinderling PH, Garrett ER, Wester RD.

J Pharm Sci. 1977 Feb;66(2):242-53.

PMID:
839422
44.

Biased bioavailability estimates.

Hinderling PH.

J Pharm Sci. 1976 Jul;65(7):1099-100. No abstract available.

PMID:
957127
45.

Pharmacodynamics of the antiarrhythmic disopyramide in healthy humans: correlation of the kinetics of the drug and its effects.

Hinderling PH, Garrett ER.

J Pharmacokinet Biopharm. 1976 Jun;4(3):231-42. No abstract available.

PMID:
978390
46.

Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.

Hinderling PH, Garrett ER.

J Pharmacokinet Biopharm. 1976 Jun;4(3):199-230. No abstract available.

PMID:
978389
47.

Protein binding and erythrocyte partitioning of disopyramide and its monodealkylated metabolite.

Hinderling PH, Bres J, Garrett ER.

J Pharm Sci. 1974 Nov;63(11):1684-90. No abstract available.

PMID:
4427225

Supplemental Content

Loading ...
Support Center